ãã€ãªå»è¬åäŒæ¥ã§ãã Akebia Therapeutics, Inc. ã¯ãè
èç
æ£è
ã®ããã®è
èæ²»çè¬ã®éçºãšåååã«æ³šåããŠããŸããå瀟ã®äž»å補åã§ããæ²»éšè¬åè£ã¯çµå£æ²»çè¬ã§ãããããã¥ã¹ã¿ããã§ãéæäŸåããã³ééæäŸåã®æäººæ£è
ã®æ
¢æ§è
èç
(CKD) ã«ããè²§è¡ã®æ²»çè¬ãšããŠç¬¬ III çžéçºæ®µéã«ãããŸããå瀟ã¯ãŸããéæãåããŠããæäºº CKD æ£è
ã®è¡æž
ãªã³æ¿åºŠã®å¶åŸ¡ãããã³éæãåããŠããªãæäºº CKD æ£è
ã®éæ¬ ä¹æ§è²§è¡ã®æ²»çè¬ãšããŠäœ¿çšãããã¯ãšã³é
žç¬¬äºéã§ãã Auryxia ãæäŸããŠããŸããAkebia Therapeutics, Inc. ã¯ãç±³åœã欧å·é£åããã·ã¢ãäžåœããªãŒã¹ãã©ãªã¢ãã«ãããäžæ±ããã³ãã®ä»ã®åœã
ã§ãããã¥ã¹ã¿ããã®éçºãšåååãè¡ãããã倧å¡è£œè¬æ ªåŒäŒç€Ÿãšææºå¥çŽãçµãã§ããŸãããŸããæ¥æ¬ããã³ã¢ãžã¢è«žåœã«ããããããã¥ã¹ã¿ããã®éçºããã³åååã«ã€ããŠã¯ãäžè±ç°èŸºè£œè¬æ ªåŒäŒç€ŸãšææºãããŸããäœé
žçŽ èªå°å åãããªã³æ°Žé
žåé
µçŽ ãæšçãšããååç©ã®äžçèŠæš¡ã§ã®éçºããã³åååã«ã€ããŠã¯ãã€ã³ã»ã³ãã¡ãŒãã·ã¥ãŒãã£ã«NVãšç ç©¶ããã³ã©ã€ã»ã³ã¹å¥çŽãç· çµããŠããŸããåœç€Ÿã¯2007幎ã«èšç«ãããããµãã¥ãŒã»ããå·ã±ã³ããªããžã«æ¬ç€Ÿã眮ããŠããŸãã